{"name":"Quanta Therapeutics","slug":"quanta-therapeutics","ticker":"","exchange":"","domain":"quanta.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"QTX3034","genericName":"QTX3034","slug":"qtx3034","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"QTX3034","genericName":"QTX3034","slug":"qtx3034","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOeEs5VktoNk03eTNSUGk2SlBOckZnZDVuTXpNbDZmX2ZxYXYzbUxTMGM5MWNKLUp2amp2RndER1BiTTR2MlRkWGRCMnVlM2U1TFA3cGh5Ym85alJ5R1NnVVhPNnI4WE1GdDRRYnRFejRHZGhfSExRYlUxUk1OOThxdA?oc=5","date":"2026-03-13","type":"pipeline","source":"pharmaphorum","summary":"Changing Faces: Pharma and biotech, February 2026 - pharmaphorum","headline":"Changing Faces: Pharma and biotech, February 2026","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-05","type":"trial","source":"GlobeNewswire","summary":"Quanta Therapeutics Presents Preclinical Data Establishing - GlobeNewswire","headline":"Quanta Therapeutics Presents Preclinical Data Establishing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUHNYZWgzclJmMURUcUp6S3ZXWENoaUtocWctcmtaSFp3TzZiMVlrcU03ZmFlYkN1b1VDMEE5ZHBiTXotU2d3bXNscWIyeENCVG5PZHZtRElDM3FmRlNqTDFXVVMxbHVQa1lBVGY1enFvRW1lOFB1LXNzdHcyTVJqdU5POHpkVzl0ZzFrUW5qTDBreEdWdGwxNHhYYWtzYzdET19XaFp3cEY2Mm8?oc=5","date":"2026-02-06","type":"trial","source":"endpoints.news","summary":"Geoff McDonough’s big plans for NodThera’s NLRP3; Enhertu leader steps down at Daiichi - endpoints.news","headline":"Geoff McDonough’s big plans for NodThera’s NLRP3; Enhertu leader steps down at Daiichi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNa3V4ZWxLV1VDLXptT25vR0U2OHJ5el92RFFFUkpvN2xMSDlSWW9rVHRQQlFVekYxdDAyRnJOVU8wa2VxODI3eUpQSkpleTVQVkZ5Tlp1VlZMd1RnSXJPcFVfazliN0s4azZkNl9lUWZ6T0RuLWJOTkpZdnMtSngxdDdxMl9FSHBXbjF0TW1TOUQ5VzJYWDRuQk1oSEVMYVNLYzNvSQ?oc=5","date":"2026-02-02","type":"pipeline","source":"Contract Pharma","summary":"Alterome Therapeutics Appoints Leonardo Faoro as New CMO - Contract Pharma","headline":"Alterome Therapeutics Appoints Leonardo Faoro as New CMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQWHBhYVhQano3WXNIV0UwaU9RcGttX1N1ektjNlBWRnpCeTZ5Q205b0FhT0Jyd3J4OVJ6V2NBQkFiRzlSTjctdjNVdmV4V0lCZjJmNGhlS2EtY0ZOZW0ydVhqbmpTY3NMOHBFMUxqMVVLSHVWZWJIVUlTWnV0OEFwR3dSbE5KbVFSNnQxaHBkQTJEeWk0LVpOSDgyTmN1OF9Yb1A2NjJMaEJqRV9FN3VvNENydEw4Ymx4cmZja3h2a19TcWxsTjZUUg?oc=5","date":"2026-02-02","type":"pipeline","source":"Business Wire","summary":"Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer - Business Wire","headline":"Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNSnZ4SW4yT0RRZ1JHWVNoeWhBTDBTNFRHZkJlcGlxZE84emhmUzUxQUpsSlZtM015aWRGN0hJTk1HTUlqdmNRcG5RZnBpTmk3UnR3WTFCUEtGYUNkX3VLY1k1MmhaQ2J2Q3djZ2V4eS1rbk1PX1RoSmFuOWx0b3JxYXB4ME5lZ2ZfV2E0OW9PSzRFTU5F?oc=5","date":"2026-01-28","type":"regulatory","source":"Yahoo Finance","summary":"Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - Yahoo Finance","headline":"Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Qualit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"nature.com","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - nature.com","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxQdS1KRmRCWnBySldRQmhtY3Vma0g1TE5HYnQ5dEdrT0RkMkxLWWJXUmFjM1Y5VThXSGYtRjNHaE9Zb2xPb3o1QlJobklaU0xmbjFYaVp4b0hMUExmdTVlVzZkYkdTWjV5amVmX0J1VWFWRm1QTFVvX21MbEVOMVBiZXVZRHRmLWkyczlOQUhfSFpwSE96cnRyUXBRdy1XM0lVcmNaSlpnZTBHa2JYQ2hHdEJOZ0U3c0dxcDNGajF4REplQUNsTENlczlTMFdZMXVfOHExd3BOQzNSd0RwOTZGVmtLZExhTTN1T3NkY3BYQXN2bVVCSXVERGNSQjdnbldRZ3cwRFR4VzJtLXV0cUVERl9iS2FhQk5XWnR2NlNId0hZWjVxalpzckJ6a2hWNk4wcmpQSXVfOGRKSjJleGpz?oc=5","date":"2025-10-24","type":"trial","source":"GlobeNewswire","summary":"Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - GlobeNewswire","headline":"Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patient","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNQ3ZIT3V5T3pwOWZpdk5Mc2trbDAwYTd5dmh5SHJDQ2hwYUdGWGtWTmsycmE3TVN5cTdHR01zZi1jaHZiRy1tUlJ5b0p5SUhIRHVFaDNpdThFU0NpSE1CUmtialIwa18yQURLVHpkUzAwSGxQTUkwU0VoMXNxSFpyRlBfamppUl9TNmFpeEZZYjZET1pkM1ZzVGMzU3Q?oc=5","date":"2025-08-12","type":"deal","source":"BioWorld News","summary":"Bayer secures KRAS G12D inhibitor with $1.3B Kumquat deal - BioWorld News","headline":"Bayer secures KRAS G12D inhibitor with $1.3B Kumquat deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdVNZU2FlX2NDTzVkZ2w4dzMyaVFCbDhKRGRmYVBiZ2JPMlBYUVBZX0tQZzFwQzZ5QXBuQWpKSkRhejBtMWh0dlh5OHZUUUE0ZnQtSzNZdTRVakp1cTZYUDNWSVlCMmItd0FXT1c3YkJiWFhSZmFTejZsaWxXdmxGZWtjc1pkdnpfQjVPaVZTeDNJNWtKWHh3YUxhR0g2QWp4QUxqR0RhbFhnSXM?oc=5","date":"2025-07-25","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Ikena and Inmagene choose CEO for soon-to-be-combined company - Fierce Biotech","headline":"Chutes & Ladders—Ikena and Inmagene choose CEO for soon-to-be-combined company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOTTB0WHN4a2JJNXBhSmFyNmNGYXJTdWJIU3FNUWlDeDZ0ZDJJc2NvM1NNMWszd3BFYmo4bm4zRElTUEUtYUlLQlFuRXowblhVdWk3aVh4QkQwMEFiXzdxVDdrc0xaUHpMRlB2SFVkY3J0c1UxcHZ6S2d6N083aldxSnY4YlNYTjd4ZHdXck5leFJXbzNEMWcwcEZ2ZkN2akdWT0hMU0VrLXljYndTUERQNkltZlE0bXk0aldLeXhlM3RhbXUwQllPYUMxREphSXQ1amFKdFhtaElQeE04UDItZk5CNV9nemN3MnN5MTJR?oc=5","date":"2025-07-23","type":"pipeline","source":"GlobeNewswire","summary":"Quanta Announces Leadership Team Appointment and Highlights Clinical Program Progress - GlobeNewswire","headline":"Quanta Announces Leadership Team Appointment and Highlights Clinical Program Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE5paEhqVWwwVmJOT2tsMVQ5WV92QlptWWd4OXN0MXJ3UjlJRkx5MmlDRzlyajdJelZONTExWmF3Y2lOZGJsdnl5bTRWTjRGX01jWXdYRTdBWUJTVC1kS1hTOTh1S29VOHFpbHRzLXdQd1FzMUJ1ZnVCLXZQMkU?oc=5","date":"2024-02-07","type":"trial","source":"Oncology Pipeline","summary":"Jazz joins the KRAS band with Redx deal | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Jazz joins the KRAS band with Redx deal | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}